<code id='846FAFDCA7'></code><style id='846FAFDCA7'></style>
    • <acronym id='846FAFDCA7'></acronym>
      <center id='846FAFDCA7'><center id='846FAFDCA7'><tfoot id='846FAFDCA7'></tfoot></center><abbr id='846FAFDCA7'><dir id='846FAFDCA7'><tfoot id='846FAFDCA7'></tfoot><noframes id='846FAFDCA7'>

    • <optgroup id='846FAFDCA7'><strike id='846FAFDCA7'><sup id='846FAFDCA7'></sup></strike><code id='846FAFDCA7'></code></optgroup>
        1. <b id='846FAFDCA7'><label id='846FAFDCA7'><select id='846FAFDCA7'><dt id='846FAFDCA7'><span id='846FAFDCA7'></span></dt></select></label></b><u id='846FAFDCA7'></u>
          <i id='846FAFDCA7'><strike id='846FAFDCA7'><tt id='846FAFDCA7'><pre id='846FAFDCA7'></pre></tt></strike></i>

          entertainment

          entertainment

          author:leisure time    Page View:83
          A scientist working at SQZ Biotechnologies in Watertown's Arsenal Yards. -- biotech coverage from STAT
          A scientist working at SQZ Biotechnologies in Watertown, Mass. David L Ryan/Globe Staff

          Next stop: Beacon Hill.

          Governor Maura Healey’s long-awaited plan to double down on state funding for the biotech and medical technology sector came into focus Thursday with the announcement she’ll seek $1 billion over the next decade to reauthorize the state’s 16-year-old life sciences initiative.

          advertisement

          But lawmakers so far are noncommittal on funding the plan. The proposal — dubbed “Life Sciences 3.0″ — is part of a larger economic development bill the Healey administration is expected to file soon. Several expressed support for an industry in which Massachusetts is a leader, but also noted the spending request comes at a time of competing priorities.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024
          JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

          EricTokatisco-presidentofinvestmentbankingatCenterviewPartners.CourtesyCenterviewPartnersSANFRANCISC

          read more
          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more

          Independent physicians launch a new lobbying group

          PaulBerggreen,agastroenterologistatArizonaDigestiveHealthwhoformedanewlobbyinggroupforindependentphy